In the phase 3 OptiTROP-Lung06 study, which was run by Kelun in 455 Chinese patients, sac-TMT reduced the risk of disease ...

Nubeqa is a key growth product for Bayer, with sales up around 60% to €1.63 billion in the first half of this year from its ...

The full look at the results of the DeLLphi-305 study of Imdelltra (tarlatamab) and Imfinzi (durvalumab) as first-line maintenance therapy for extensive-stage SCLC (ES-SCLC) whose disease had not ...

VOLGA was conducted in patients with MIBC ineligible or unwilling to take platinum-based chemotherapy, who received PD-L1 inhibitor Imfinzi (durvalumab) before and after surgery to remove the tumour, ...

Jazz Pharma has dipped its toe into the M&A water again, agreeing to buy epilepsy drug developer Actio Biosciences in a deal that includes an upfront payment of $820 million. Privately-held Actio is ...

Legislation that would restrict US organisations from contracting with some Chinese biotech providers has been passed by a House of Representatives committee, moving closer to becoming law. First ...

The FDA has started a priority review of AstraZeneca's IL-33-targeting antibody tozorakimab for chronic obstructive pulmonary disease (COPD), setting up a decision on the would-be blockbuster in the ...

Office of Management and Budget (OMB) Director Russell Vought. A move by the Trump administration to block new NIH research funding for external research teams, as well as some renewals, appears to ...

A hacking group claims to have broken into AstraZeneca's IT systems and stolen confidential data, which they are now offering for sale. The group, known as LAPSUS$, maintain that they have stolen ...

UK contract development and manufacturing organisation (CDMO) Oxford BioMedica confirmed this morning that it has received an unsolicited approach from private equity group EQT about a possible ...

Lundbeck has announced a major change to its commercial strategy, withdrawing from 27 markets and handing day-to-day operations to partner companies. The move – described as a "sharpening" of ...

The FDA has approved software from medical artificial intelligence (AI) firm Caption Health, that allows medical professionals without specialised training to perform cardiac ultrasound. The software ...